易方达恒生港股通创新药ETF联接发起式C (024329.jj ) 恒生港股通创新药指数申 | 基金类型指数型基金(ETF,联接型)成立日期2025-06-20总资产规模 (2025-09-30) 基金净值1.0449元 (2025-12-24) 基金经理成曦管理费用率0.50%管托费用率0.10% (2025-11-18) 成立以来分红再投入年化收益率4.75% (523 / 1316) |
| 相关基金: | 主从基金: 易方达恒生港股通创新药ETF联接发起式A目标基金: 易方达恒生港股通创新药ETF |
| 备注 (0): | 双击编辑备注 |
易方达恒生港股通创新药ETF联接发起式C(024329) - 基金对比
最后更新于：2025-12-24
非全收益率指数点位的计算不包含分红再投入，所以理论上指数基金的分红再投入收益率高于其对应的指数点位涨幅。
加载中......
| 日期 | 易方达恒生港股通创新药ETF联接发起式C - 相对起始点分红再投入收益率 | 恒生港股通创新药指数 - 相对起始点收益率 |
|---|---|---|
| 2025-12-24 | 4.75% | 55.63% |
| 2025-12-23 | 5.41% | 56.59% |
| 2025-12-22 | 5.45% | 56.61% |
| 2025-12-19 | 6.19% | 57.79% |
| 2025-12-18 | 4.80% | 55.49% |
| 2025-12-17 | 4.26% | 54.67% |
| 2025-12-16 | 3.98% | 54.20% |
| 2025-12-15 | 4.81% | 55.47% |
| 2025-12-12 | 9.36% | 62.70% |
| 2025-12-11 | 7.82% | 60.10% |
| 2025-12-10 | 8.23% | 60.63% |
| 2025-12-09 | 8.95% | 61.71% |
| 2025-12-08 | 10.14% | 63.70% |
| 2025-12-05 | 12.01% | 66.68% |
| 2025-12-04 | 11.81% | 66.41% |
| 2025-12-03 | 9.95% | 63.43% |
| 2025-12-02 | 11.80% | 66.38% |
| 2025-12-01 | 13.24% | 68.67% |
| 2025-11-28 | 13.71% | 69.22% |
| 2025-11-27 | 14.73% | 70.79% |
| 2025-11-26 | 13.86% | 69.30% |
| 2025-11-25 | 11.99% | 66.40% |
| 2025-11-24 | 11.34% | 65.34% |
| 2025-11-21 | 8.10% | 60.12% |
| 2025-11-20 | 12.94% | 67.74% |
| 2025-11-19 | 11.94% | 66.23% |
| 2025-11-18 | 12.69% | 67.21% |
| 2025-11-17 | 14.48% | 70.10% |
| 2025-11-14 | 16.76% | 73.66% |
| 2025-11-13 | 17.42% | 74.59% |
| 2025-11-12 | 12.42% | 66.71% |
| 2025-11-11 | 9.79% | 62.52% |
| 2025-11-10 | 9.90% | 62.78% |
| 2025-11-07 | 8.44% | 60.42% |
| 2025-11-06 | 11.13% | 64.62% |
| 2025-11-05 | 10.79% | 63.99% |
| 2025-11-04 | 10.28% | 63.17% |
| 2025-11-03 | 13.39% | 68.22% |
| 2025-10-31 | 11.32% | 64.66% |
| 2025-10-30 | 7.74% | 58.98% |
| 2025-10-29 | 9.54% | -- |
| 2025-10-28 | 9.58% | 61.82% |
| 2025-10-27 | 11.00% | 63.99% |
| 2025-10-24 | 10.37% | 62.95% |
| 2025-10-23 | 10.40% | 63.02% |
| 2025-10-22 | 12.45% | 66.18% |
| 2025-10-21 | 14.91% | 70.08% |
| 2025-10-20 | 14.95% | 70.02% |
| 2025-10-17 | 13.95% | 68.51% |
| 2025-10-16 | 17.56% | 74.48% |